PEGS Boston - Protein and Antibody Engineering Summit

April 30–May 4, 2018
Boston, MA, USA

Meet Genedata experts at PEGS Boston Protein Engineering Summit in Boston, MA.

Don't miss the opportunity to see how Genedata solutions efficiently support the whole biopharmaceutical R&D workflow, including screening and protein engineering, expression and purification, characterization and analysis of protein therapeutics, cell line design and development, bioprocess optimization, and quality control of biologicals.

To get more information about Genedata solutions, please contact info@genedata.com.

Recommended Oral Presentations

Multi-tasking for Multi-specific Targets at Sanofi
Leila Sevigny, Ph.D., Senior Scientist, Sanofi Genzyme

Display as a Tool for Discovery Session
Tuesday, May 1 | 14:35–15:05

Multi-specific antibodies result from complex engineering processes that increase organizational and throughput needs.  Sanofi has made multi-specific antigen creation, screening and engineering more efficient by using Genedata Biologics, an integrated workflow platform that enables molecule, sample and assay data tracking from generation to final candidates.  We show how the system not only provides a shared repository to track all the pertinent data associated with the project from start to finish, but also allows us to draw conclusions by cross-project data mining and learn from our experience for future discovery campaigns.

Industrializing IO Therapeutic Discovery Platforms: Multispecifics, Engineered TCRs and CARs
Maria Wendt, PhD, Head of Science, Biologics, Genedata

Bispecific vs. CAR T Approach: Direct Comparision Session
Thursday, May 3 | 15:20–15:50

Novel classes of bio-molecules are currently evaluated for their use in cancer immunotherapy. Bi- and multi-specific antibodies, Ab-cytokine fusion proteins, non-Ig scaffolds, chimeric antigen receptors (CARs), engineered TCRs and TCR-based bispecific constructs promise significant advantages. However, these highly engineered molecules pose new challenges in design, engineering, cloning, expression, purification, and analytics. Genedata Biologics offers an infrastructure that addresses these challenges and enables the industrialization of these various novel therapeutic platforms.

Automated Data Processing and Analysis for Quality Monitoring of Biotherapeutics by Multi- Attribute Method (MAM)
Joe Shambaugh, Head Genedata Expressionist, Genedata 

Characterization of Biotherapeutics: Characterization for novel drug formats
Monday, April 30 | 1:20–1:50

Mass spectrometry (MS) enables simultaneously measurement of multiple biotherapeutic critical quality attributes (CQAs) at the molecular level. Applying a multi-attribute method (MAM) can increase product quality while reducing development and manufacturing costs. We present a MAM implementation using a single software platform for processing, analysis, and management of MS data. Dedicated workflows for a given biomolecule were tailored to measure CQAs, test for impurities, and check system suitability.

Recommended Poster Presentations

Poster Session A
Monday & Tuesday | April 30–May 1

Industrializing IO Therapeutic Discovery Platforms: Multispecifics, Engineered TCRs and CARs
Maria Wendt, Head of Science, Biologics, Genedata

A Novel Integrated End-to-End Workflow System Enabling Increased Throughput in Bioprocess Development
Andrew Lynch, Scientific Consultant, Genedata

Automated Data Processing and Analysis by Quality Monitoring of Biotherapeutics by Multi- Attribute Method (MAM)
Joe Shambaugh, Head Genedata Expressionist, Genedata 

Enterprise Mass Spectrometry Software Solution Enabling Characterization of Biotherapeutics from Discovery and Development to Production and Quality Control
Cassandra Wigmore, Business Account Manager, Genedata

Poster Session B
Wednesday & Thursday | May 2–3

First-In-Class Expression and Characterization Request Management System to Increase Biotherapeutics R&D Operational Efficiency
Adrienne Craig-Kennard, Scientific Consultant, Genedata

Automated Intact Mass Analysis for the Characterization of Antibodies
David Bush, Scientific Account Manager, Genedata 

Large-scale Determination of Affinity, Specificity, and Kinetics of Complex Molecules: Automating Data Analysis at Pace with the New Possibilities
Lope Florez, Head of Scientific Account Management, Genedata

Deep Learning Enables Easy Switching of HCS Modalities, From Small to Large Molecules and Between Human Donors
Stephan Steigele, Head of Science, Screener, Genedata

Links:
www.pegsummit.com